BRPI0614524B8 - uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto, e o referido composto - Google Patents

uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto, e o referido composto

Info

Publication number
BRPI0614524B8
BRPI0614524B8 BRPI0614524A BRPI0614524A BRPI0614524B8 BR PI0614524 B8 BRPI0614524 B8 BR PI0614524B8 BR PI0614524 A BRPI0614524 A BR PI0614524A BR PI0614524 A BRPI0614524 A BR PI0614524A BR PI0614524 B8 BRPI0614524 B8 BR PI0614524B8
Authority
BR
Brazil
Prior art keywords
alkyl
compound
hydrogen
combination
het
Prior art date
Application number
BRPI0614524A
Other languages
English (en)
Inventor
Koul Anil
Francis Alain Lançois David
Thérése Jeanne Pasquier Elisabeth
Emile Georges Guillemont Jérôme
Jozef Lodewijk Marcel Andries Koenraad
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35768940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0614524(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BRPI0614524A2 publication Critical patent/BRPI0614524A2/pt
Publication of BRPI0614524B1 publication Critical patent/BRPI0614524B1/pt
Publication of BRPI0614524B8 publication Critical patent/BRPI0614524B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto, e o referido composto. a presente invenção refere-se ao uso de um composto para a fabricação de um medicamento para o tratamento de uma infecção bacteriana desde que a infecção bacteriana seja diferente de uma infecção micobacterina, o referido composto sendo um composto de fórmula (la) ou (lb) um sal de adição de ácido ou de base farmaceuticamente aceitável do mesmo, uma amina quaternária do mesmo, uma forma estereoquimicamente isomérica do mesmo, uma forma tautomérica do mesmo ou uma forma n-óxido do mesmo, em que r1 é hidrogênio, halo, haloalquila, ciano, hidróxi, ar, het, alquila, alquilóxi, alquiltio, alquiloxialquila, alquiltioaíquila, ar-alquila ou di (ar) alquila; p é 1, 2 ou 3; r2 é hidrogénio; alquila; hidróxi; mercapto; alquilóxi opcionalmente substituido; alquiloxialquilóxi; alquiltio; mono ou di (alquil) amino em que alquila pode ser opcionalmente substituida; ar; het ou um radical de fórmula (ii); r3 é alquila, ar, ar-alquila, het ou het-alquila; q é zero, 1, 2, 3 ou 4; x é uma ligação direta ou ch2; r4 e r5 cada independentemente são hidrogênio, alquila ou benzila; ou e r5 podem ser tomados juntos incluindo o n ao qual eles são fixados; r6 é hidrogênio ou um radical de fórmula; r7 é hidrogênio, alquila, ar ou het; r8 é hidrogênio ou alquila; r9 é oxo; ou e r9 juntos formam o radical -ch=ch-n=.
BRPI0614524A 2005-08-03 2006-07-31 uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto, e o referido composto BRPI0614524B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05107159.5 2005-08-03
EP05107159 2005-08-03
PCT/EP2006/064856 WO2007014940A2 (en) 2005-08-03 2006-07-31 Quinoline derivatives as antibacterical agents

Publications (3)

Publication Number Publication Date
BRPI0614524A2 BRPI0614524A2 (pt) 2011-04-05
BRPI0614524B1 BRPI0614524B1 (pt) 2020-05-19
BRPI0614524B8 true BRPI0614524B8 (pt) 2021-05-25

Family

ID=35768940

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0614524A BRPI0614524B8 (pt) 2005-08-03 2006-07-31 uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto, e o referido composto

Country Status (28)

Country Link
US (1) US8017606B2 (pt)
EP (1) EP1912647B1 (pt)
JP (1) JP5410753B2 (pt)
KR (1) KR101337237B1 (pt)
CN (1) CN101277695B (pt)
AR (1) AR054889A1 (pt)
AU (1) AU2006274879B2 (pt)
BR (1) BRPI0614524B8 (pt)
CA (1) CA2615901C (pt)
CY (1) CY1114908T1 (pt)
DK (1) DK1912647T3 (pt)
EA (1) EA014832B1 (pt)
ES (1) ES2437575T3 (pt)
HR (1) HRP20131116T1 (pt)
IL (1) IL189141A (pt)
JO (1) JO2952B1 (pt)
MX (1) MX2008001602A (pt)
MY (1) MY148241A (pt)
NO (1) NO341247B1 (pt)
NZ (1) NZ565283A (pt)
PL (1) PL1912647T3 (pt)
PT (1) PT1912647E (pt)
RS (1) RS53065B (pt)
SI (1) SI1912647T1 (pt)
TW (1) TWI381839B (pt)
UA (1) UA95916C2 (pt)
WO (1) WO2007014940A2 (pt)
ZA (1) ZA200801108B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2512364B2 (ja) 1992-03-02 1996-07-03 共栄電工株式会社 筒状の被加工物の内面研磨方法および装置
US7902225B2 (en) * 2004-01-23 2011-03-08 Janssen Pharmaceutica Nv Mycobacterial inhibitors
JO2952B1 (en) 2005-08-03 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO2683B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO3271B1 (ar) * 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
US20110059948A1 (en) * 2008-01-14 2011-03-10 Jyoti Chattopadhyaya Quinoline, naphthalene and conformationally constrained quinoline or naphthalene derivatives as anti-mycobacterial agents
JP5246715B2 (ja) 2009-01-27 2013-07-24 独立行政法人科学技術振興機構 蛋白質架橋阻害剤およびその用途
WO2010144102A1 (en) * 2009-06-09 2010-12-16 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of U.S. Army Medical Research And Material Command Pentafluorosulfanyl analogs of mefloquine
ES2576491T3 (es) 2012-04-27 2016-07-07 Janssen Pharmaceutica, N.V. Derivados de quinolina antibacterianos
AU2013254670B2 (en) 2012-04-27 2017-03-30 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
MY189505A (en) 2012-10-16 2022-02-16 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of roryt
WO2014062655A1 (en) 2012-10-16 2014-04-24 Janssen Pharmaceutica Nv HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt
HK1213887A1 (zh) 2012-10-16 2016-07-15 Janssen Pharmaceutica N.V. RORγt的苯基连接的喹啉基调节剂
WO2014070760A1 (en) 2012-10-30 2014-05-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of resazurin, or analogs thereof, for antibacterial therapy
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
CN105636952A (zh) 2013-10-15 2016-06-01 詹森药业有限公司 Rorγt的仲醇喹啉基调节剂
CA2927182A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Quinolinyl modulators of ror.gamma.t
CA2926339A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of roryt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
GB201904796D0 (en) * 2019-04-04 2019-05-22 Univ Sheffield Antimicrobial agent
AR121683A1 (es) * 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4
AR121682A1 (es) * 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4
US20240287022A1 (en) * 2021-06-28 2024-08-29 Merck Sharp & Dohme Llc Il4i1 inhibitors and methods of use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317491D0 (en) * 1993-08-23 1993-10-06 Fujisawa Pharmaceutical Co New compound and a process for preparation thereof
US6376670B1 (en) * 1997-06-19 2002-04-23 Sepracor Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
GB9914486D0 (en) 1999-06-21 1999-08-18 Smithkline Beecham Plc Medicaments
GB9917408D0 (en) * 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
GB0101577D0 (en) * 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
AR040336A1 (es) * 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto
SI1527050T1 (sl) * 2002-07-25 2010-08-31 Janssen Pharmaceutica Nv Kinolinski derivati in njihova uporaba kot mikobakterijski inhibitorji
JP4602903B2 (ja) 2002-10-10 2010-12-22 モルフォケム アクチェンゲゼルシャフト フュア コンビナトリシェ ヘミー 抗菌活性を有する新規化合物
DE10316081A1 (de) * 2003-04-08 2004-10-21 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
NZ546990A (en) * 2003-11-20 2010-03-26 Janssen Pharmaceutica Nv 7-Phenylalkyl substituted 2-quinolinones and 2 quinoxalinones as poly(adp-ribose) polymerase inhibitors
JP4806353B2 (ja) * 2003-12-05 2011-11-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ポリ（ａｄｐ−リボース）ポリメラーゼインヒビターとしての６−置換２−キノリノンおよび２−キノキサリノン
US7902225B2 (en) * 2004-01-23 2011-03-08 Janssen Pharmaceutica Nv Mycobacterial inhibitors
JO2952B1 (en) 2005-08-03 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents

Also Published As

Publication number Publication date
JP2009503024A (ja) 2009-01-29
CN101277695A (zh) 2008-10-01
MX2008001602A (es) 2008-02-19
NO341247B1 (no) 2017-09-25
NZ565283A (en) 2011-07-29
KR101337237B1 (ko) 2013-12-06
RS53065B (sr) 2014-04-30
BRPI0614524B1 (pt) 2020-05-19
WO2007014940A3 (en) 2007-03-29
EA200800501A1 (ru) 2008-10-30
WO2007014940A8 (en) 2007-07-05
HRP20131116T1 (hr) 2013-12-20
EP1912647B1 (en) 2013-09-11
US8017606B2 (en) 2011-09-13
EP1912647A2 (en) 2008-04-23
EA014832B1 (ru) 2011-02-28
PL1912647T3 (pl) 2014-02-28
ZA200801108B (en) 2009-05-27
UA95916C2 (ru) 2011-09-26
JO2952B1 (en) 2016-03-15
IL189141A0 (en) 2008-08-07
CA2615901A1 (en) 2007-02-08
NO20080955L (no) 2008-02-25
AU2006274879B2 (en) 2013-01-10
CY1114908T1 (el) 2016-12-14
AU2006274879A1 (en) 2007-02-08
BRPI0614524A2 (pt) 2011-04-05
AR054889A1 (es) 2007-07-25
KR20080038380A (ko) 2008-05-06
MY148241A (en) 2013-03-29
TWI381839B (zh) 2013-01-11
US20080255116A1 (en) 2008-10-16
SI1912647T1 (sl) 2014-01-31
TW200744594A (en) 2007-12-16
DK1912647T3 (da) 2013-12-02
PT1912647E (pt) 2013-12-05
CA2615901C (en) 2014-06-03
JP5410753B2 (ja) 2014-02-05
IL189141A (en) 2015-10-29
HK1124233A1 (en) 2009-07-10
WO2007014940A2 (en) 2007-02-08
ES2437575T3 (es) 2014-01-13
CN101277695B (zh) 2011-12-14

Similar Documents

Publication Publication Date Title
CY1114908T1 (el) Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες
BRPI0506400B8 (pt) uso de um composto para a fabricação de um medicamento para o tratamento de tuberculose latente
ATE457988T1 (de) A2a-adenosin-rezeptor-antagonisten
BRPI0614493B8 (pt) uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto, processo para a preparação de um composto e o referido composto
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
CY1113535T1 (el) Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες
ATE490958T1 (de) Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate
CY1113579T1 (el) Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες
NZ547277A (en) Substituted quinolines and their use as mycobacterial inhibitors
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.
NO20080481L (no) Kinolinderivater som antibakterielle midler
EA200970496A1 (ru) Соединения 2-алкилиндазола для лечения некоторых расстройств цнс
MXNL06000098A (es) Compuesto como antagonistas de ccr5.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/05/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/07/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2786 DE 28-05-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.